Teleflex Incorporated research snapshot
TFX AI stock analysis currently reads Teleflex Incorporated as a specialized medical device company whose underlying procedural demand supports its hospital and critical care product lines, but whose GAAP earnings have been distorted by large impairment charges that make conventional valuation unreliable. At the July 12, 2026 data cutoff, TFX traded near $135.48, had a calculated market capitalization near $5.95 billion, and generated TTM revenue of approximately $2.13 billion. The company carries significant debt, near-zero trailing GAAP EPS, and a forward P/E near 20x that assumes a return to normalized profitability. This TFX AI stock analysis uses scenario ranges, not a guaranteed price prediction, and it is informational research rather than investment advice.
Current price
$135.48
Market cap
$5.95 billion calculated, $6.00 billion reported reference
AI score
58 / 100
Rating
Small-cap medtech undergoing post-impairment stabilization with valuation uncertainty near forward earnings power
Trend status
Improving but incomplete: price has recovered from the 52-week low near $100 but sits below the 52-week high near $140 with mixed momentum signals
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Teleflex sells single-use medical devices for vascular access, interventional cardiology, surgery, and emergency medicine. The product portfolio has clinical utility but many categories face meaningful competition. | Medium |
| Moat | Modest moat from physician training, regulatory clearances, and brand recognition in niche categories like intraosseous access (EZ-IO) and vascular closure (MANTA). However, switching costs vary by product line and several categories are competitive. | Medium-low |
| Management | CEO Jason Weidman has emphasized pipeline investment (Freesolve scaffold) and debt refinancing, but the large impairment charges raise questions about past acquisition strategy and capital allocation discipline. | Medium-low |
| Financial trend | TTM revenue of approximately $2.13 billion with low single-digit organic growth. GAAP profitability destroyed by impairment charges. Normalized earning power is debated and likely well below historical levels. | Medium |
| Valuation | At $135.48, TFX trades near 20x forward EPS estimates, 2.8x TTM revenue, 1.9x book value, and 31.7x EV/EBITDA. All these multiples are hard to evaluate given the impairment-distorted base period. | Low-medium |
| Technical trend | The stock has recovered from its 52-week low of $100.18 and is testing resistance near $140. RSI and MACD signals are mixed; the trend is improving but not confirmed. | Medium |
| Risk level | Risk is elevated. Debt of approximately $3 billion against $333 million cash, negative GAAP earnings, modest organic growth, competitive pressure in core categories, and limited margin of safety. | Medium |
| AI confidence | Data quality is moderate but the big impairment charges make the TTM base period unreliable for valuation. Forward estimates depend heavily on normalization assumptions. | Medium data confidence |
| Investment certainty | TFX has some attractive product franchises but the overall risk/reward is unclear given debt, earnings quality uncertainty, and modest growth. The margin of safety is narrow. | Medium-low |
TFX AI stock forecast
The TFX AI stock forecast uses scenario math around the $135.48 price reference, a normalized forward EPS estimate near $6.68 derived from the forward P/E of 20.28x, and a three-year earnings multiple framework. The audited model produced a bearish area near $86, a base area near $155, and a bullish area near $222 before dividends and future capital allocation effects.
$200 to $225
More likely if Freesolve scaffold and MANTA vascular closure drive above-trend growth, organic revenue accelerates to 8-10%, operating margins recover meaningfully, debt is reduced, and investors assign a mid-20s earnings multiple.
$145 to $165
More likely if organic revenue grows 4-6%, normalized EPS compounds near mid-single digits, free cash flow improves modestly, and TFX holds a low-20s earnings multiple in line with small-cap medtech peers.
$75 to $95
More likely if revenue growth stagnates, additional impairment charges emerge, competitive pressure intensifies in core catheter and surgical categories, operating margins compress, or leverage restricts financial flexibility.
TFX AI technical analysis
TFX AI technical analysis shows an improving but incomplete picture as of the July 12, 2026 cutoff. Yahoo Finance showed TFX at $135.48 with a 52-week range of $100.18 to $139.67. The stock is near the top of its 52-week range which signals recovery momentum, but it has not yet confirmed a breakout above the $140 resistance zone. TradingView indicators showed mixed signals with neutral buy/sell consensus.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $135.48 | Yahoo Finance listed TFX at $135.48 as of the July 12, 2026 data cutoff. |
| Immediate support | $130 to $132 | Recent pullback support zone from the prior weeks. Holding this level maintains the short-term recovery structure. |
| Key support | $100.18 | The 52-week low is the major downside reference. A move toward this level would indicate a failed recovery. |
| Near resistance | $139.67 to $140 | The 52-week high is the immediate ceiling. A clean break above this zone would signal a new uptrend leg. |
| Extended resistance | $160 | The average analyst price target near $145 to $146 sits below this level. A move above $160 would require a significant improvement in operating fundamentals. |
| Momentum | RSI neutral, MACD mixed | The daily technical snapshot shows mixed indicators, neither clearly overbought nor oversold. |
| Volume and volatility | Medium monitoring priority | Earnings on July 30, 2026, product news on Freesolve and MANTA, and debt refinancing updates can change the setup quickly. |
| Invalidation | Close below $125, then $100 | A close below $125 would weaken the recovery case. A move below the 52-week low at $100.18 would invalidate the constructive framework. |
TFX AI trading strategy
The TFX AI trading strategy below is a rules-based research framework, not personal advice. It connects Teleflex fundamentals, normalized EPS recovery, debt profile, and technical confirmation with predefined invalidation levels.
Watch for TFX to break and hold above $140 with above-average volume. Confirmation should include positive earnings on July 30, 2026, evidence of organic revenue acceleration, and no adverse news on debt, impairments, or competitive losses.
A failed breakout followed by a close below $130 should reduce setup confidence because it would show the recovery lacks conviction.
If TFX pulls back toward $120 to $125 without a guidance cut or impairment news, compare the selloff with revenue trends, cash flow trajectory, debt maturity schedule, and medtech peer group performance.
Do not treat weakness as a buying opportunity if it is tied to lowered guidance, new impairment risks, or deterioration in the competitive position of key product lines.
Track total debt, cash position, debt maturity schedule, interest coverage, free cash flow generation, and any refinancing activity. The debt load of roughly $3 billion against $333 million cash is the primary risk factor.
Position sizing should reflect leverage risk, GAAP earnings uncertainty, competitive intensity in core categories, hospital budget pressure, and the fact that a 1% dividend yield provides minimal income buffer.
Investment research summary
Teleflex is paid because hospitals need reliable single-use medical devices for vascular access, interventional cardiology, surgical procedures, and emergency care. The customer value is procedural efficiency, patient safety, and clinical reliability across a broad product catalog.
Teleflex has moderate competitive advantages in niche categories such as intraosseous access (EZ-IO), vascular closure (MANTA), and surgical ligation (Weck). However, many product lines face competition from larger medtech players and the switching costs vary significantly by category.
The thesis fails if the impairment charges reflect systemic overpayment for past acquisitions, if organic growth stagnates below 3%, if debt restricts strategic flexibility, if competitive pressure erodes margins in core categories, or if normalized earning power is materially below market expectations.
CEO Jason Weidman has focused the company on pipeline innovation including the Freesolve resorbable magnesium scaffold and MANTA vascular closure. The capital allocation track record is mixed given large impairment charges, and the key question is whether current R&D spending can return the company to reliable earnings growth.
Aging populations, rising chronic disease prevalence, adoption of minimally invasive procedures, and growth in interventional cardiology support long-term demand for Teleflex products. However, hospital cost containment, group purchasing organization pricing pressure, and medtech consolidation create headwinds.
At $135.48 with a forward P/E near 20x, TFX is not priced for distressed value. The margin of safety depends on whether normalized EPS can reach and sustain the $6.50 to $7.00 range, whether revenue growth accelerates, and whether debt can be managed without restricting investment.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $135.48 as of July 12, 2026 | Yahoo Finance TFX quote | July 12, 2026 |
| Shares outstanding | Approximately 43.91 million shares | TradingView TFX fundamentals | July 12, 2026 |
| Market capitalization verification | $5.95 billion calculated from $135.48 x 43.91M shares, compared with $6.00 billion reported reference | Pineify financial_rigor.py and Yahoo Finance market cap reference | July 12, 2026 |
| TTM revenue | Approximately $2.13 billion | Yahoo Finance TFX statistics | July 12, 2026 |
| GAAP net income (TTM) | $1.36 million, diluted EPS $0.05 | Yahoo Finance TFX statistics | July 12, 2026 |
| FY net income (most recent fiscal year) | -$905.64 million, reflecting large impairment charges | TradingView TFX fundamentals | July 12, 2026 |
| Enterprise value | $8.31 billion | Yahoo Finance TFX statistics | July 12, 2026 |
| Cash and equivalents | $333.06 million | Yahoo Finance TFX balance sheet | July 12, 2026 |
| Debt and leverage | Total debt/equity 88.79%; estimated total debt approximately $3 billion | Yahoo Finance TFX statistics | July 12, 2026 |
| Forward valuation | Forward P/E 20.28x, EV/Revenue 3.91x, EV/EBITDA 31.68x | Yahoo Finance TFX statistics | July 12, 2026 |
| 52-week price range | $100.18 to $139.67 | Yahoo Finance TFX quote | July 12, 2026 |
| Dividend | $1.36 annual, 1.01% yield | Yahoo Finance TFX statistics | July 12, 2026 |
| Analyst consensus and target | Average target $145.89, with Piper Sandler at $160 (Overweight) and Argus at HOLD with targets ranging $130 to $143 | Yahoo Finance TFX analysis | July 12, 2026 |
| Three-scenario fair value (3-year) | Bullish $222, Base $155, Bearish $86 per Pineify financial_rigor.py | Pineify financial_rigor.py three-scenario model using normalized EPS $6.68 | July 12, 2026 |
This TFX AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 12, 2026 and may be wrong if Teleflex revenue growth, impairment charges, debt management, competitive dynamics, market multiples, interest rates, or investor sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
